GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Aims:
The purpose of this study is to compare the effects of two different treatment in patients with endometrial cancer that has not spread outside of the abdomen. This study also aims to determine if radiation therapy combined with chemotherapy is more effective than chemotherapy alone. Another purpose of this study is to collect tissue and blood samples from patients with advanced endometrial cancer to see if special tests can be used to determine which patients may respond to treatment, or have a better prognosis, and which patients may have side effects. Patients will receive either chemotherapy and radiation for 4 cycles, or chemotherapy alone for 6 cycles.
Diagnosis: Advanced Endometrial Carcinoma
Principal Investigator: Jean Hurteau,MD
IRB Approval Number: EH09-534
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698 
Open to Enrollment: Yes 

Amgen 20060517: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Aims: The purpose of this study is to test whether using the investigational drug AMG 386 in combination with PLD (Pegylated Liposomal Doxorubicin, a traditional chemotherapy agent) improves the outcome of treatment, compared to treatment with PLD chemotherapy alone. AMG 386 is designed to stop the growth of blood vessels in cancer tissues and has not been approved by the FDA (Food and Drug Administration). All study subjects will receive traditional PLD therapy, but not all will receive AMG 386.
Diagnosis: Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH11-138
Sponsor: Amgen, Inc.
Contact: Interested patients should contact study coordinator Sharon Goldman at 847.570.1173
Open to Enrollment: No

GOG 0261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin vs Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Aims: The purpose of this study is to compare the drugs carboplatin and paclitaxel to standard treatment for uterine and ovarian carcinosarcoma.  The standard treatment consists of paclitaxel plus the drug ifosfamide and a bladder protecting medicine called mesna. Based on results of other clinical trials, researchers think that the combination of carboplatin and paclitaxel may be as effective as the combination of ifosfamide and paclitaxel but with fewer side effects. In this study, patients will get either the combination of paclitaxel and carboplatin or the combination of ifosfamide and mesna plus paclitaxel. All of the medications on this study are FDA-approved for the treatment of ovarian or uterine cancers.
Diagnosis: Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-015
Sponsor: Gynecologic Oncology Group (GOG)
Contact:
Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 229K: A Phase II Evaluation of BIBF 1120 (IND# 113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma 
Aims: The purpose of this study is to determine the effectiveness of the drug BIBF 1120 in treating endometrial cancer and to determine the types and severity of side effects caused by this treatment. Also, the study would like to assess whether this treatment can extend the survival of patients with recurrent endometrial cancer that is not curative by standard treatment. BIBF 1120 is not an FDA approved drug and therefore its use is investigational.
Diagnosis: Recurrent or Persistent Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-176
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: No

GOG 0274: Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Aims: The purpose of this study is to compare standard treatment; radiation therapy combined with the chemotherapy drug cisplatin (called chemo-radiation), to standard treatment plus additional investigational chemotherapy with the FDA approved agents, carboplatin and paclitaxel. The study will see if the addition of these chemotherapy agents will reduces the risk of tumor recurrence and improves overall survival.
Diagnosis: Cervical Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-455
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Aims: The major goal of this study is to see if physicians can predict how women will tolerate and complete chemotherapy as prescribed using simple assessments looking at your ability to do activities of daily living. Another goal of the study is to look at how chemotherapy works in older women with cancer, and for this reason you will be asked to allow some research blood to be drawn in order to measure the amount of chemotherapy drug(s) in your blood.
Diagnosis: Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-186
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG-2001/Amgen 20101129 (TRINOVA-3): A Phase 3 Randomized Double-Blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-Line Treatment of Subjects with FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Aims: AMG 386 is a drug designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow. The purpose of this study is to find out more about AMG 386 in addition to standard treatment in people with advanced epithelial ovarian, primary peritoneal or fallopian tube cancers.
Diagnosis: Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-067
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: No

Randomized Controlled Pilot Trial of Vitamin D3 Replacement or Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
Aims:Some research studies have shown that Vitamin D may reduce the risk of some cancers, including ovarian cancer. This study will examine if high dose Vitamin D is tolerable, and see what effects it may have on cells in the ovary related to the biology of cancer, including how cell growth and cell death is regulated. Information gained from this study may help direct future research studies.
Diagnosis: Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Gustavo Rodriguez, MD
IRB Approval Number: EH13-222
Sponsor: Northwestern University
Contact: Interested patients should contact Sharon Goldman at 847.570.1173
Open to Enrollment: Yes

× Alternate Text